A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Ac

Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Back to Results

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Objective

Clinical Trial Details

Principal Investigator(s)

Waqas Jehangir, MD

Clinical Trial Categories

Cancer

Contact

Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

Avera Cancer Institute — Sioux Falls
1000 E 23rd St
Suite 340
Sioux Falls, SD 57105
Main: 605-322-3000